Skip to content
Menu

Charles River Laboratories International, Inc. CRL

Full chart Compare
Set alert

Price alert · CRL

All alert types
333.25 USD +1.09 (+0.33%)

Regular-session close

330.09 -3.16 -0.95%

Pre-market · Nov 19, 4:01 AM ET

330.41 Day range 338.28
146.20 52-week range 379.63
YTD
+67.06%
1 year
+105.04%
Market cap
15.97B
Revenue (ttm)
3.98B
Profit margin
1.01%
EPS (ttm)
0.92
Shares out
47.92M
P/E ratio
362.23
Forward P/E
25.68
YTD return
+67.06%
1-year return
+105.04%
50-day average
313.03
Volume
516.21K
Avg volume
1.05M
Open
332.15
Previous close
332.16
Day's range
330.41 – 338.28
52-week range
146.20 – 379.63
Beta
1.34
Analysts
Buy
Price target
350.57 (+5.2%)
Earnings date
Feb 17, 2027

5D +6.33 (+1.93%)

330335340ThuFriMonTueWed333.56

Key statistics

200-day average
228.93
Enterprise value
18.62B
PEG ratio
0.12
Price / sales
4.01
Price / book
4.94
Revenue growth
-2.20%
Free cash flow
443.24M
Total cash
200.38M
Total debt
2.85B
Return on equity
1.27%
Short % of float
7.20%

Fundamental scorecard

7 of 25 checks passed on CRL’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 0 of 5
  • Growth 3 of 5
  • Profitability 2 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Sep 26, 2026.

Financials — quick view

All financials
CRL Revenue — quarterly 982.73M
CRL Net income — quarterly 333.07M
CRL EPS — quarterly 6.97

Earnings

CRL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 17, 2027Dec 26, 20263.32———
Nov 4, 2026Sep 26, 20262.973.09+0.12+4.04%
Aug 5, 2026Jun 27, 20262.743.02+0.28+10.22%
May 7, 2026Mar 28, 20261.962.06+0.10+5.10%
Feb 18, 2026Dec 27, 20252.332.39+0.06+2.58%
Nov 5, 2025Sep 27, 20252.322.43+0.11+4.74%

Upgrades / downgrades

CRL analyst upgrades and downgrades
DateFirmActionFromTo
Nov 5, 2026UBSmainBuyBuy
Nov 5, 2026RBC CapitalmainOutperformOutperform
Nov 5, 2026BarclaysmainOverweightOverweight
Nov 5, 2026Evercore ISI GroupmainOutperformOutperform
Oct 13, 2026Morgan StanleymainOverweightOverweight
Sep 28, 2026JefferiesmainBuyBuy

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
criver.com

News

Your note

Sign in to keep a note on CRL — it syncs with the Stock Master app.

Insider holders

CRL insider holders
InsiderRelationLatest transactionDateShares held
COLEMAN GLENN GChief Financial OfficerStock Award(Grant)May 28, 202627,752
CREAMER VICTORIA LOfficerConversion of Exercise of derivative securityAug 5, 202630,051
FOSTER JAMES CDirectorConversion of Exercise of derivative securityOct 21, 2026233,410
GIRSHICK BIRGITChief Executive OfficerStock GiftAug 18, 202679,288
KNELL MICHAEL GUNNAROfficerConversion of Exercise of derivative securityAug 5, 202611,852
LAPLUME JOSEPH WOfficerStock GiftAug 9, 202631,041

Institution ownership

CRL institution ownership
Holder% heldSharesValueReported
FMR, LLC12.46%5,971,7011.99BSep 29, 2026
Blackrock Inc.7.88%3,777,3801.26BSep 29, 2026
Vanguard Capital Management LLC6.53%3,127,8231.04BSep 29, 2026
Price (T.Rowe) Associates Inc6.28%3,008,0491.00BSep 29, 2026
Vanguard Portfolio Management LLC4.57%2,189,157729.21MSep 29, 2026
State Street Corporation3.91%1,873,871624.19MSep 29, 2026

Fund ownership

CRL fund ownership
Holder% heldSharesValueReported
Fidelity Contrafund4.31%2,065,737688.10MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.19%1,530,171509.70MJun 29, 2026
HARRIS ASSOCIATES INVESTMENT TRUST-Oakmark Select Fund3.13%1,498,000498.98MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.60%1,247,732415.62MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.31%1,104,850368.03MJun 29, 2026
Invesco Exchange-Traded Fund Trust-Invesco S&P 500 Equal Weight ETF1.47%702,813234.11MSep 29, 2026